11/06/2026
The videos are now available! 🎥
You can now watch the recorded testimony and public comments from the October 28, 2026, FDA Rare Disease Framework Initiative public meeting.
I had the privilege of participating in this historic conversation and providing public comment on the need to rethink how we approach rare disease drug development.
For patients and families living with rare diseases, this initiative represents an important opportunity to address the realities of developing treatments for small patient populations, where traditional regulatory expectations may not always reflect the evidence that can realistically be generated.
The FDA, in partnership with the Reagan-Udall Foundation for the FDA, is seeking public input on several critical areas:
* Fit-for-purpose evidence: Evaluating therapies based on the specific disease, disease state, patient population, and attainable evidence.
* Regulatory consistency: Improving predictability and consistency in FDA drug development and review requirements.
* Patient and expert engagement: Ensuring patients, disease experts, and researchers have a meaningful voice in regulatory decision-making.
* Chemistry, Manufacturing & Controls (CMC): Addressing the unique manufacturing and development challenges associated with rare disease therapies.
This conversation cannot end with a public meeting. It needs to translate into meaningful regulatory reform and, ultimately, better pathways to treatments for patients who cannot afford to wait.
If you are part of the rare disease community, a researcher, clinician, advocate, or industry stakeholder, I encourage you to watch the testimony and make your voice heard.
There is still an opportunity to submit written public comments.
📅 Deadline: December 11, 2026
📌 FDA Docket: FDA-2026-N-12214
Submit comments electronically through Regulations.gov or by written submission.
Our voices matter. The science matters. And the patients waiting for treatments matter most.
https://reaganudall.org/news-and-events/events/rare-disease-framework-public-meeting?eType=EmailBlastContent&eId=be0fc3c4-189f-4698-92a0-973c2b95f409
Reagan-Udall Foundation for the FDA, independent 501(c)(3) organization created by Congress to advance the mission of the Food and Drug Administration.